Dear Dan:
I was just kidding of course and I do appreciate your thoughtful insights into this TMR subject. Lord knows that on the Yahoo board there is very little of substance ever mentioned although burnthru and cardiohands are excellent contributors as are you.
The following article is just another shot across the shorts bow.
This stock like others I have owned and own is in the precarious position of similar to a woman about o give birth and the shorts are the abortionists. They are hoping to turn the corner and those that hang in there will be well rewarded when the gestation period is ended fruitfully. Yuri was a similar stock in a differet industry as is OCOM and Schick Tecnologies.
Altruism aside the question must be asked which ones are worth the wait. Which one is going to be the next MSFT in its field?
Regards,
John
PR Newswire, Friday, May 08, 1998 at 09:18
FRANKLIN, Mass., May 8 /PRNewswire/ -- PLC Systems Inc. (AMEX:PLC) today
announced that, at the 78th Annual Meeting of the Association of Thoracic
Surgeons, clinicians from Boston, Massachusetts presented findings from a
breakthrough study involving gene therapy and transmyocardial
revascularization (TMR) using The Heart Laser System.
Clinicians studied 29 pigs with artificially-induced diseased hearts
displaying abnormal wall motion (wall motion is a determinant of the overall
vitality of the heart muscle). Animals were assigned different treatment
modalities including: no treatment, TMR only, gene therapy only and TMR in
combination with direct injection of the gene, VEGF. Left ventricular free-
wall motion was assessed by a cardiologist in a blinded (not informed of
treatment modality) manner at six weeks after treatment.
The TMR-gene therapy group displayed no evidence of wall motion
abnormality post treatment. Researchers concluded that these results suggest
that the combined use of TMR with direct injection of the gene, VEGF
completely reverses ischemic (diseased) wall motion abnormalities in this
animal model.
William C. Dow President and CEO of PLC Systems stated, "Both TMR using
The Heart Laser System and gene therapy are exciting new therapies in the
fight against coronary artery disease. Studies such as the research conducted
in Boston continue to demonstrate TMR's potential therapeutic benefit not only
as a sole therapy, but as a possible enhancement to other therapies such as
VEGF. By combining the two therapies physicians may be able to provide
patients a more complete revascularization than either therapy would alone." |
